Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet

Core Viewpoint - Design Therapeutics, Inc. (DSGN) has seen a 23.7% increase in share price over the past four weeks, closing at $5.01, with a potential upside of 39.7% based on Wall Street analysts' mean price target of $7 [1] Price Targets - The average price target consists of three short-term estimates ranging from a low of $4 to a high of $12, with a standard deviation of $4.36, indicating variability among analysts [2] - The lowest estimate suggests a decline of 20.2% from the current price, while the highest estimate indicates a potential upside of 139.5% [2] Analyst Sentiment - Analysts show strong agreement regarding DSGN's ability to report better earnings than previously predicted, which supports the view of potential upside [4] - The Zacks Consensus Estimate for the current year has increased by 7.4% over the past month, with two estimates revised higher and no negative revisions [10] Zacks Rank - DSGN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [11]